Avast appoints Nick Viney to lead Telco, IoT security business
by Maria Thomas | Updated Jun 17, 2020
In his role, Viney will oversee Avast's global strategy for the business unit and will lead the development of the company's position in smart home security while expanding its overall portfolio of security products and partners including telecommunications providers and Original Equipment Manufacturers (OEMs).
Viney joins Avast from Cyber 1, a publicly listed enterprise cybersecurity provider, where he was Group CEO.
Prior to that, he held Regional Vice President roles at McAfee in both the consumer and corporate sectors during his time there.
"Avast is a company I have long admired for its commitment to innovation, focus on the customer and for its mission to make the world a safer place for everyone, particularly the most vulnerable in our society," Viney said on his appointment.
"These are values I have stood by throughout my entire career and I'm looking forward to leading some important projects for the company that are tackling real-world cybersecurity problems and issues for consumers today."
Viney also held leadership positions within the consumer, SMB and enterprise business units at Google and Microsoft.
His experience covers multiple channels to market including the mobile and carrier sector and the IoT market as well as OEM and retail.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report